Andernach

This research aims to learn about the effects of etrasimod as a treatment for adults aged 18 to 64 with moderate to severe ulcerative colitis. Patients included have not taken etrasimod before and are prescribed this treatment based on their physicians judgment as the best option. The study is observational and non-interventional, focusing on real-world use of etrasimod. All participants will receive etrasimod according to standard medical care. The study does not change treatment schedules but includes regular health questionnaires completed online by patients using their own devices. The treatment and assessments follow usual care practices throughout the 52-week study period, followed by a 28-day safety follow-up. Participants will visit their doctors as usual and complete health questionnaires regularly via a mobile phone, tablet, or computer. Researchers will compare each patients disease activity before and after starting etrasimod, focusing on symptomatic remission and clinical response at weeks 12 and 52. Safety is monitored during and after treatment, with the total participation lasting about one year and one month.

Researchers are conducting a prospective, non-interventional observational study to understand how patients aged 6 years and older with atopic dermatitis AD respond to treatment with dupilumab in everyday medical practice. The study aims to characterize these patients by examining their medical history, demographic and disease-related features, associated allergic conditions, other type 2 inflammation diseases, and their past and current treatments. The study will also assess the long-term effectiveness and safety of dupilumab over two years, focusing on disease control and quality of life.

Researchers are evaluating the safety and initial effectiveness of mesenchymal stromal cells MSCs derived from umbilical cord tissue to treat cartilage damage in the knee joint. This prospective, multicenter, single-arm, open-label clinical trial focuses on patients with symptomatic cartilage defects who are candidates for surgical cartilage regeneration. The study aims to provide detailed safety data and early efficacy outcomes over a two-year period following treatment. Eligible patients will undergo arthroscopic or minimally invasive knee surgery during which the investigational product, called MesemCart, containing 10 to 20 million UC-MSCs applied to a collagen carrier, will be placed once directly on the cartilage defect. All participants receive this same treatment and are followed up regularly for 24 months. The study includes a single treatment arm without any placebo or comparison groups. Participants will be monitored through scheduled visits up to two years after surgery to assess safety, including serious adverse events, and to evaluate cartilage regeneration using imaging scores and patient-reported outcomes. These outcomes include pain levels, knee-related quality of life, symptoms, stiffness, activities of daily living, and physical resilience during sports, measured at 12 and 24 months. Safety will be tracked continuously, with all adverse events documented and assessed throughout the study.

Ulcerative colitis UC is a chronic inflammatory bowel disease causing inflammation and bleeding in the rectum and large intestine. This research aims to assess changes in disease activity in adults with moderate to severe UC who are treated with risankizumab in real-world clinical practice. The study will observe approximately 200 adult participants prescribed risankizumab by their physicians in Germany and Austria. Participants will receive risankizumab as prescribed by their doctors according to the approved local label and routine clinical care. The study does not introduce additional treatments or procedures beyond what is normally provided. Participants will be followed for up to 52 weeks while continuing their usual medication schedule. Throughout the study, participants will attend regular hospital or clinic visits as part of their routine care. Researchers will track the percentage of participants achieving symptomatic remission using the Partial Adapted Mayo Score over about 52 weeks. There is no expected added burden, and participants will receive standard monitoring and care during this period.